- feeds
- popular
- recent
- reader
- about
- story
- technologies
- what is rss
- connect
- dmca
- contact
- Feed Preview MEDIA
Roche to present new and encouraging long-term follow-up data across broad haematology portfolio at ASH 2024
Basel, 05 November 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will present more than 40 abstracts across nine blood disorders at the 66th American Society of Hematology (AS...
Roche presents new data at CTAD, demonstrating its growing momentum in diagnostics for Alzheimer’s disease
NEW DATA HIGHLIGHT THE POTENTIAL OF THE ROCHE ELECSYS® AMYLOID PLASMA PANEL AND ELECSYS PTAU181 FOR RULING OUT ALZHEIMER’S DISEASE RELATED AMYLOID PATHOLOGY WITH VERY GOOD ACCURACY. IN THE LA...
New England Journal of Medicine publishes landmark phase II...survival in certain type of HR-positive advanced breast cancer
ITOVEBITM (INAVOLISIB)-BASED REGIMEN DEMONSTRATED A STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL BENEFIT, REDUCING THE RISK OF DISEASE WORSENING OR DEATH BY 57% COMPARED WITH PALBOCICLIB ...
Roche’s strong sales growth of 9% (CER) continues in the...rter of 2024; Group sales increase 6% in the first nine months
GROUP SALES grew by 6%1 at constant exchange rates (CER) (2% in CHF) in the first nine months, driven by the high demand for both our medicines and diagnostics; excluding COVID-19-related produc...
Roche’s Vabysmo improved vision in underrepresented popul...with diabetic macular edema (DME) in a first-of-its-kind study
THE ELEVATUM STUDY SHOWED CLINICALLY MEANINGFUL IMPROVEMENT IN VISION AND REDUCTION IN RETINAL FLUID IN PEOPLE WITH DIABETIC MACULAR EDEMA (DME) TREATED WITH VABYSMO WHO IDENTIFY AS AFRICAN AMER...
Majority of children with spinal muscular atrophy (SMA) tre...o sit, stand and walk independently, two-year data demonstrate
POSITIVE DATA CONFIRM EVRYSDI EFFICACY AND SAFETY IN CHILDREN FIRST TREATED PRE-SYMPTOMATICALLY BEFORE SIX WEEKS OF AGE, WITH MOST ACHIEVING MOTOR MILESTONES SIMILAR TO CHILDREN WITHOUT SMA ALL ...
FDA approves Roche’s Itovebi, a targeted treatment for ad...r-positive, HER2-negative breast cancer with a PIK3CA mutation
APPROVAL IS BASED ON PHASE III INAVO120 RESULTS, SHOWING THE ITOVEBI™ (INAVOLISIB)-BASED REGIMEN MORE THAN DOUBLED PROGRESSION-FREE SURVIVAL COMPARED WITH PALBOCICLIB AND FULVESTRANT ALONE IN ...
Roche obtains CE certification for the first companion diag...eal junction cancer eligible for targeted treatment with VYLOY
THE NEW VENTANA CLDN18 (43-14A) RXDX ASSAY HELPS FULFIL AN UNMET MEDICAL NEED BY ENABLING CLINICIANS TO IDENTIFY PATIENTS WITH GASTRIC OR GASTROESOPHAGEAL JUNCTION (GEJ) CANCER WHO MAY BENEFIT F...
Positive phase III results for Roche’s Gazyva/Gazyvaro sh...ority to standard therapy alone in people with lupus nephritis
POSITIVE PHASE III RESULTS FOR ROCHE’S GAZYVA/GAZYVARO SHOW SUPERIORITY TO STANDARD THERAPY ALONE IN PEOPLE WITH LUPUS NEPHRITIS THE REGENCY STUDY MET ITS PRIMARY ENDPOINT, DEMONSTRATING STATIS...
Roche launches the first test to use its breakthrough TAGS ...h throughput, simultaneous detection of 12 respiratory viruses
NEW TAGS (TEMPERATURE-ACTIVATED GENERATION OF SIGNAL) TECHNOLOGY ENABLES UP TO 15 TARGETS TO BE DETECTED SIMULTANEOUSLY IN A SINGLE PATIENT SAMPLE ON THE HIGH THROUGHPUT MOLECULAR DIAGNOSTIC ANA...